Larimar kept in limbo as FDA maintains clinical hold on leading candidate

The FDA is keeping its clinical hold on Larimar Therapeutics' leading candidate to treat Friedreich’s ataxia and is requesting additional data, the company announced Tuesday.

In August, Larimar said it was confident that there was a path forward toward resolving the hold on CTI-1601 and moving on to Jive open-label extension and pediatric multiple ascending dose trials by the first half of this year.